Atopic dermatitis is a chronic inflammatory disease that can arise during the first months of life or at maturity and have a significant negative impact on the quality of life. The main pathogenic mechanism is the breakdown of cutaneous barrier integrity, which is associated with systemic inflammatory immunologic disorders. Atopic dermatitis involves numerous immunologic, allergic, respiratory, and ophthalmologic comorbidities that develop through similar intricate pathogenic phenomena. The atopic march represents the evolution in time of various allergic diseases, of which food allergies often cause the first manifestations of atopy, even from a very young age. Chronic inflammation translated through specific markers, next to increased immunoglobulin E (IgE) serum levels and heterogenous clinical manifestations, argue for the inclusion of atopic dermatitis in the systemic disease category.
Acne is an inflammatory dermatosis of the pilosebaceous unit that remains highly prevalent worldwide. In recent decades, the epidemiological profile of acne has evolved, with a rising incidence observed not only among adolescents but also in adult populations, particularly adult women. The current global prevalence is approximately 9.4%, reflecting its continued relevance as a public health concern. While early epidemiological studies were predominantly conducted in the United States and United Kingdom, recent data from diverse geographic regions highlight the need for updated, globally representative research. The Global Burden of Disease (GBD) initiative has recognized acne as a condition with a substantial impact on disability-adjusted life years (DALYs), underscoring its contribution to both physical and psychological morbidity. This review aims to synthesize current epidemiological findings, identify high-risk populations, and explore intrinsic and extrinsic factors influencing disease distribution and progression. A deeper understanding of acne’s epidemiology is essential to inform prevention strategies and improve outcomes in dermatological care.
Basal cell carcinoma (BCC) is the most common form of cutaneous neoplasia in humans, and dermoscopy may provide valuable information for histopathological classification of BCC, which allows for the choice of non-invasive topical or surgical therapy. Similarly, dermoscopy may allow for the identification of incipient forms of BCC that cannot be detected in clinical examination. The importance of early diagnosis using the dermoscopy of superficial BCC forms is proven by the fact that despite their indolent clinical appearance, they can be included in high-risk BCC forms due to the rate of postoperative recurrence. Nodular pigmentary forms of BCCs present ovoid gray-blue nests or multiple gray-blue dots/globules associated with arborized vessels, sometimes undetectable on clinical examination. The management of BCC depends on this, as pigmentary forms have been shown to have a poor response to photodynamic therapy. High frequency ultrasound examination (HFUS) aids in the diagnosis of BCC with hypoechoic tumour masses, as well as in estimating tumour size (thickness and diameter), presurgical margin delineation, and surgical planning. The examination is also useful for determining the invasion of adjacent structures and for studying local recurrences. The use of dermoscopy in combination with HFUS allows for optimisation of the management of the oncological patient.
Methotrexate is an immunosuppressive drug with remarkable therapeutic results in the treatment of autoimmune and proliferative skin diseases. Although it has been more than half a century since it was first introduced into the therapeutic arsenal of dermatologists, there are currently no standardized therapeutic protocols regarding the prescription of methotrexate in dermatology, with the exception of psoriasis treatment. This review aims to highlight the indications and benefits of methotrexate beyond psoriasis, with a focus on a wide range of inflammatory, vesiculobullous, and proliferative dermatological pathologies.
Psoriasis vulgaris is a polygenic, immunomediated dermatological condition, characterized pathophysiologically by abnormal proliferation of the epidermis and immune response disorders, evidenced by the presence of a dermal inflammatory infiltrate accompanied by exocytosis. The prevalence of this disease is continuously increasing, and the significant impact on quality of life is determined by both the severity of the skin manifestations and the associated comorbidities, which underlines the importance of early diagnosis. Among the imaging methods useful in the diagnosis and monitoring of psoriasis vulgaris are dermatoscopy and high-frequency cutaneous ultrasonography (HFUS). Dermatoscopy is a valuable complementary imaging tool in assessing the therapeutic response in patients with psoriasis vulgaris. Although clinical lesions may show partial or complete remission, the persistence of the specific vascular architecture—characterized by dilated and branched capillaries—suggests the maintenance of disease activity and justifies the need for continued treatment. HFUS allows the identification of characteristic changes in psoriatic plaques, such as homogeneous thickening of the epidermis, visible as a hyperechoic band, the presence of a hypoechoic subepidermal band, and thickening of the dermis. Evaluation with 20 MHz probes can significantly contribute to monitoring therapeutic efficacy, since the first observable changes under topical and/or systemic treatment include a reduction in the thickness of the epidermis, dermis, and hypoechoic subepidermal band. The integration of dermatoscopy and HFUS within the clinical evaluation allows for a complex and precise approach to the management of patients with psoriasis vulgaris, facilitating objective monitoring of disease progression and appropriate adjustment of therapy.
Psoriasis is not considered a strictly skin condition, but a complex disease with multisystem involvement due to the frequent associated comorbidities. We conducted a retrospective database study of 10,986 patients admitted in the interval January 2008–January 2019 to the Dermatology Clinic of the Iasi County “St. Spiridon” Emergency Hospital. Of the 10,986 patients admitted, 1288 were diagnosed with psoriasis. The association of malignancies was found in 40 of the psoriasis group cases and 399 of the control group cases that included various dermatological conditions. The calculation of Odds Ratios allowed us to determine if the patients with psoriasis could be at risk for certain malignancies. Thus, an association was suggested between psoriasis and central nervous system (CNS), upper aerodigestive tract cancer, endocrine cancer, bladder cancer, lung cancer, prostate cancer, breast cancer, or colorectal cancer. It is the first study of its kind in the northeastern region of Romania and can be the starting point for future long-term prospective cohort studies that will allow a more accurate data collection and a better understanding of the psoriasis–cancer relationship.
About Me
Emergency St. Spiridon Hospital from Iasi & "Gr. T Popa" University of Medicine and Pharmacy, Iasi
Emergency St. Spiridon Hospital from Iasi & "Gr. T Popa" University of Medicine and Pharmacy, Iasi